The University of Edinburgh
Determination of the utility of autologous macrophage therapy in chronic liver disease
Abstract
dc:description.abstractAdvanced chronic liver disease (ACLD) is characterised by the presence of advanced bridging fibrosis, with constitutional architectural re-organisation of the liver parenchyma. It represents a growing disease, with an increase in mortality of over 400% since 1970, compared with all other forms of chronic disease including cancer. The principle aetiologies are encompassed by the umbrella term of “steatotic liver disease “ (SLD) and are most often attributable to metabolic dysfunction-associated steatotic liver disease (MASLD) (formerly non-alcoholic fatty liver disease (NAFLD)), and alcohol-related liver disease (ArLD), followed by the viral hepatitides. Current therapeutic options are limited and consist of managing complications, with liver transplant an option for a subset of individuals. Liver transplantation is challenging for a number of physiological and ethical reasons, and there are insufficient organs available, and deaths are increasingly common in those awaiting transplantation. Therefore, there is enormous need to develop additional therapies which ameliorate fibrosis, enabling restitution of intrinsic liver functionality for some, while bridging others until a suitable liver graft becomes available. This thesis firstly reviews the use of cell-based therapeutics, including pre-clinical models, and subsequently assessing translational studies in those with both acute and chronic liver failure syndromes. It addresses some of the key challenges that remain to be overcoming including biological challenges in recapitulating native hepatocyte function in variant syndromes, in addition to optimising cell delivery approaches as part of an effective treatment option. In ACLD resident monocyte and macrophage-derivative cells have diverse roles within the liver microenvironment. This thesis presents the methodology paper underpinning our clinical study, including study design, randomisation and development of primary and secondary outcomes. It presents the typical trial matrix which trial participants adhered to as part of the MATCH01 study. Latterly, the thesis examines the clinical outcomes of the phase II randomised, controlled trial of autologous macrophage therapy. This trial utilised peripherally - isolated monocytes, which were subsequently matured and reintroduced into individuals with ACLD in a Scottish cohort. The thesis further explores in more depth important secondary endpoints including; exploratory imaging and fibrosis assessments, biochemical markers of fibrosis, and quality of life evaluations of those involved in an advanced cell-based therapy trial for cirrhosis. Finally, the thesis looks to the future utility of this therapeutic approach in shifting the paradigm of ACLD and significant challenges relating to morbidity, mortality and overall burden of disease.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Brennan, Paul Noel
- Advisors dc:contributor.advisor
-
- Forbes, Stuart
- Fallowfield, Jonathan
Subjects
dc:subject × 4Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/6679